Evaluation of Ruxolitinib and Pracinostat Combination as a Therapy for Patients With Myelofibrosis
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs Pracinostat (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis; Myeloproliferative disorders
- Focus Therapeutic Use
- 26 Jun 2018 Status changed from active, no longer recruiting to completed.
- 21 Mar 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2021.
- 21 Mar 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History